Datasheet for ABIN6809865

CD20 Protein (AA 1-297) (His tag)

3 Images

Go to Product page

Overview

Quantity:	100 µg
Target:	CD20 (MS4A1)
Protein Characteristics:	AA 1-297
Origin:	Human
Source:	HEK-293 Cells
Protein Type:	Recombinant
Biological Activity:	Active
Purification tag / Conjugate:	This CD20 protein is labelled with His tag.

Product Details

Sequence:	AA 1-297
Purity:	>85 % as determined by SDS-PAGE.
Endotoxin Level:	Less than 1.0 EU per µg by the LAL method.

Target Details

Target:	CD20 (MS4A1)
Alternative Name:	CD20 (MS4A1 Products)
Background:	B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity.

Target Details

	CD20 is expressed on all stages of B cell development except the first and last, it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5), also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.
Molecular Weight:	35.2 kDa
NCBI Accession:	NP_068769

Application Details

Restrictions:	For Research Use only

Handling

Format:	Liquid
Buffer:	50 mM HEPES, 150 mM NaCl, DDM, CHS, pH 7.5
Handling Advice:	Please avoid repeated freeze-thaw cycles.
Storage:	-80 °C



ELISA

Image 1. Immobilized Rituximab at 2 µg/mL (100 µL/well) can bind Human CD20 Full Length, His Tag, HEK293 (SPR verified) (ABIN6731296,ABIN6809865,ABIN6809866) with a linear range of 0.4-3 ng/mL (in presence of DDM and CHS) (QC tested).



SDS-PAGE

Image 2. Human CD20 Full Length, His Tag (HEK293) (SPR verified) on under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 85 % .



ELISA

Image 3. Immobilized Ofatumumab at 2 µg/mL (100 µ L/well) can bind Human CD20 Full Length, His Tag, HEK293 (SPR verified) (ABIN6731296,ABIN6809865,ABIN6809866) with a linear range of 0.4-6 ng/mL (in presence of DDM and CHS) (QC tested).